Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens


The aim of this study is to determine preliminary efficacy of capecitabine and interferon-alpha in second-line after interleukin-2 based regimens in patients with MRCC

Full Title of Study: “Phase II Study of Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Non-Randomized
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2008


  • Drug: capecitabine, interferon-alpha
    • Patients who meet inclusion/exclusion criteria will receive combination of study drugs.

Arms, Groups and Cohorts

  • Experimental: 1
    • All patients will receive capecitabine and interferon-alpha.

Clinical Trial Outcome Measures

Primary Measures

  • Evaluate progression-free survival with capecitabine and interferon treatment in metastatic renal cell carcinoma (MRCC) patients (pts) with IL-2 failure in first-line
    • Time Frame: one year

Secondary Measures

  • Evaluate the safety and tolerability of the capecitabine and interferon combination
    • Time Frame: one year
  • Evaluate response rate and overall survival with the capecitabine and interferon combination in MRCC pts with progression on IL-2 based regimens
    • Time Frame: one year

Participating in This Clinical Trial

Inclusion Criteria

  • Histologically or cytologically confirmed renal carcinoma – CT-confirmed metastatic sites – Must have measurable disease, defined as ≥ 1 unidimensionally measurable lesion measured as ≥ 20 mm with conventional techniques OR as ≥ 10 mm with spiral CT scan – Disease progression after IL-2 – Age 18 or older – ECOG performance status 1-3 – Life expectancy ≥ 2 months – WBC ≥ 3,000/mm3 – Platelet count ≥ 100,000/mm3 – Hemoglobin ≥ 7.5 g/dL – Creatinine ≤ 1.5 mg/dL (2.0 mg/dL in post-nephrectomy patients) – Total bilirubin ≤ 1.5 mg/dL – AST ≤ 3.0 times normal – Alkaline phosphatase ≤ 2.5 times normal (10 times ULN in presence of bone metastases) – Not pregnant or nursing – No history of autoimmune – No history of serious cardiac arrhythmia, congestive heart failure, angina pectoris, or other severe cardiovascular disease (i.e., New York Heart Association class III or IV) – No CNS metastases by neurologic exam and/or MRI – No history of seizure disorders – No local and/or systemic infections requiring antibiotics within 28 days prior to study entry – No other malignancy – Written informed consent

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Kidney Cancer Research Bureau
  • Provider of Information About this Clinical Study
    • Ilya Tsimafeyeu, MD, Kidney Cancer Research Bureau
  • Overall Official(s)
    • Ilya V. Tsimafeyeu, MD, Principal Investigator, Kidney Cancer Research Bureau
    • Lev V. Demidov, MD, DSc., Study Director, N.N. Blokhin Russian Cancer Research Bureau

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.